Food and Drug Administration Silver Spring MD 20993

Elizabeth Barbehenn, Ph.D.
Public Citizens Health Research Group
Public Citizen
1600 20th Street, NW
Washington, DC 20009

June 17, 2014

Dear Dr. Barbehenn:

We have received your June 5, 2014, letter to Dr. Woodcock in response to the Agency's denial of your citizen petition, which requested that we remove the diabetes drug liraglutide from the market.

Your letter has been forwarded to the appropriate Agency experts on these matters and will be given appropriate consideration with respect to the new drug application you reference in your letter and other related matters as applicable.

Thank you for contacting us concerning this matter.

Sincerely,

Johanna Mclatchy, M.Sc., RN

Science Policy Analyst

Food and Drug Administration

Center for Drug Evaluation and Research